Eli Lilly (LLY.N) raised 2026 full-year sales guidance to $91–92bn from $85–87bn. The company said acquisition-related effects leave expected adjusted EPS at $35–36 for the year, slightly below prior guidance. Q3 2026 revenue was $24.4bn, beating the Street consensus of $22.5bn. Diabetes drug Mounjaro generated $10.7bn in sales and weight‑loss drug Zepbound $5.35bn, both above analysts’ estimates. Management also reported progress on regulatory approvals for its products. Shares were up more tha

Eli Lilly (LLY.N) raised 2026 full-year sales guidance to $91–92bn from $85–87bn. The company said acquisition-related effects leave expected adjusted EPS at $35–36 for the year, slightly below prior guidance. Q3 2026 revenue was $24.4bn, beating the Street consensus of $22.5bn. Diabetes drug Mounjaro generated $10.7bn in sales and weight‑loss drug Zepbound $5.35bn, both above analysts’ estimates. Management also reported progress on regulatory approvals for its products. Shares were up more than 4% premarket; the stock is up nearly 20% year‑to‑date through Wednesday’s close.